Major Depressive Disorder

A recent study found that depression among caregivers was associated with a 73% increased risk of emergency department visits in patients with dementia.

A recent study of more than 50,000 found that antidepressant use could reduce a third of deaths among diabetic patients with depression.

A recent study found that every year of education was equivalent to a 2.5% reduction in risk of heart disease.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

The nasal spray was shown to reduce relapse in patients who achieved remission or stability after 16 weeks of treatment plus antidepressant.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

Mental health disorders are highly prevalent in certain patients with COPD—and their effect can limit lung function therapy benefit.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

Patients diagnosed with psoriasis face a nearly three-fold greater risk of developing anxiety disorders.

Esketamine nasal spray is currently relegated to a specific depression patient population, but that may not be for long.

From 2010 to 2017, there was an increase of over 30% in the number of commercially insured children being diagnosed with ADHD.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.

Pregnant women who suffer from asthma reported a two-fold greater risk for PPD according to the results of a large-scale Quebec hospital cohort.

A new study shows that a history of anxiety and depression drive suicidal thoughts in students, but having a significant other may limit such thoughts.

A study of 41 patients in a single center show novel results for the recently-approved treatment-resistant depression therapy.

The three-minute device complements the company's marketed TMS devices which provide care over 37.5 and 19 minutes per session.

Sustained virologic response rates were high among HCV/HIV coinfected patients with early treatment discontinuation the only factor associated with lower SVR rate.

Before the new treatment-resistant depression therapy reaches the market, Iosifescu anticipates its benefits and limitations in real-world patients.

Just 7 other states, and the District of Columbia, have passed such a law before. The bill's parameters are similar to that of Hawaii's, which passed its own law last year.

The 60-hour intravenous therapy becomes the first drug indicated for postpartum depression.

A review of suicide prediction models reveals limited practical application on larger populations.

Despite previous observations that high-quality diet correlates to lower depression symptoms, new results paint a different picture.

One of the pioneer investigators of ketamine for depression explains what its recent approval for a severe form of the condition means for patients running out of options.

The therapy becomes the first novel mechanism of action-driven drug approved for depression in 30 years.